According to the central government, the corona vaccine of Zydus Cadila can be available from the first week of October. At the same time, a decision will be taken after the opinion of the National Technical Advisory Group on Immunization i.e. NTAGI on whether it can be given to children between 12 years and 17 years. Zydus Cadila’s Corona Vaccine has recently received Emergency Use Authorization from the Drug Controller General of India. The special thing is that this is the world’s first DNA vaccine against Corona. At the same time, this is India’s first vaccine that can be given to people above 12 years of age.
Today, the Ministry of Health made it clear that Zydus Cadila’s DNA-based corona vaccine ZyCoV-D will be available from the first week of October. Zydus Cadila is India’s sixth vaccine against corona which has got emergency use authorization. This vaccine can be given to children above 12 years of age. However, from when the children will be given, it has not been decided yet. According to the Union Health Secretary, NTAGI i.e. National Technical Advisory Group on Immunization will decide about it and tell its opinion to the government, after which a decision will be taken.
Union Health Secretary Rajesh Bhushan said, “Whether priority should be given to all children or whether children with comorbidities should be given priority for vaccination, as recommended by the Standing Committee on COVID, NTAGI. Once the recommendation was made, which has not happened till now. Once what NTAGI recommends on this and then the government takes a decision on that recommendation.”
At the same time, talks between the government and the company are also going on regarding the price of the vaccine. No decision has been taken yet regarding its price. Rajesh Bhushan said, “The company will be in a position to provide this vaccine from the first week of October. That’s why we are in talks with them and we will share with you as soon as we clarify the terms and conditions of purchase. It will be available after the third week of September.
Let us tell you that this is an indigenous vaccine and its clinical trial has been done in India itself. This is a DNA based triple dose vaccine. There are three doses of this vaccine, which will be given at an interval of 4-4 weeks. Its efficiency is 66.6 percent. Injection is not used in this, but this vaccine is needle free. It can be given through jet injector. Pharmajet a needle free applicator ensures painless intradermal vaccine delivery.
The trial of this vaccine has been done on people above the age of 12 years, that is, the vaccine will be available for children above the age of 12 years. The company claims that by this year about 40 million vaccine doses will be ready.
So far a total of 6 corona vaccines have been allowed in India. Astragenica and Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik, Moderna and Johnson & Johnson’s vaccines have so far received emergency use authorization from the Drug Controller General of India in India.